NEW YORK — Fujirebio and Sysmex said on Thursday that they have signed a reagent raw material supply agreement that builds on a recently formed immunoassay assay development alliance between the Japanese companies.
In October, Fujirebio and Sysmex agreed to collaborate on the development of immunoassays that run on Sysmex's HISCL-Series automated system, with the goal of moving into an execution phase by early 2024.
In support of that deal, the companies last month struck a contract development and manufacturing organization (CDMO) agreement related to the development of reagents for cerebrospinal fluid-based and blood-based testing for neurodegenerative diseases including Alzheimer's disease.
Under that latest agreement, Fujirebio and Sysmex will both supply a range of reagent materials, primarily antigens and antibodies, to support the CDMO deal.
Additional terms were not disclosed.